GSK's RSV Vaccine Demonstrates Promising Protection for Adults 50-59

GlaxoSmithKline's RSV vaccine, Arexvy, has shown potential in protecting adults aged 50 to 59 from respiratory syncytial virus (RSV) in a late-stage clinical trial. The vaccine elicited an immune response in this age group without any adverse effects, and the safety data was consistent with that of adults aged 60 and above. GSK plans to submit the final trial results for regulatory review and expects a decision on expanding the vaccine's label in 2024. Currently, Pfizer is the only other company with an approved RSV vaccine, but it is unclear if they will present data for adults aged 50 to 59. RSV causes thousands of hospitalizations and deaths among older Americans each year.